Education
About Us
Working with TipRanks
Follow Us
Reviva Pharmaceuticals Holdings (RVPH)
NASDAQ:RVPH
Total Valuation
Reviva Pharmaceuticals Holdings has a market cap or net worth of $53.27M. The enterprise value is $8.75M.
Market Cap$53.27M
Enterprise Value$8.75M
Share Statistics
Reviva Pharmaceuticals Holdings has 96,337,120 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding96,337,120
Owned by Insiders0.09%
Owned by Institutions2.82%
Financial Efficiency
Reviva Pharmaceuticals Holdings’s return on equity (ROE) is -36.82 and return on invested capital (ROIC) is -2266.54%.
Return on Equity (ROE)-36.82
Return on Assets (ROA)-1.93
Return on Invested Capital (ROIC)-2266.54%
Return on Capital Employed (ROCE)-34.16
Revenue Per Employee0.00
Profits Per Employee-2.14M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Reviva Pharmaceuticals Holdings is ―. Reviva Pharmaceuticals Holdings’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio73.84
Price to Fair Value73.84
Price to FCF-1.79
Price to Operating Cash Flow-1.26
PEG Ratio0.04
Income Statement
In the last 12 months, Reviva Pharmaceuticals Holdings had revenue of 0.00 and earned -29.92M in profits. Earnings per share was -0.90.
Revenue0.00
Gross Profit0.00
Operating Income-30.80M
Pretax Income-29.90M
Net Income-29.92M
EBITDA-29.88M
Earnings Per Share (EPS)-0.90
Cash Flow
In the last 12 months, operating cash flow was -26.55M and capital expenditures -3.00, giving a free cash flow of -26.55M billion.
Operating Cash Flow-26.55M
Free Cash Flow-26.55M
Free Cash Flow per Share-0.28
Dividends & Yields
Reviva Pharmaceuticals Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.21
52-Week Price Change-71.30%
50-Day Moving Average0.59
200-Day Moving Average0.65
Relative Strength Index (RSI)57.69
Average Volume (3m)14.40M
Important Dates
Reviva Pharmaceuticals Holdings upcoming earnings date is Mar 23, 2026, TBA (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMar 23, 2026
Ex-Dividend Date―
Financial Position
Reviva Pharmaceuticals Holdings as a current ratio of 1.01, with Debt / Equity ratio of -24.66%
Current Ratio1.01
Quick Ratio1.01
Debt to Market Cap<0.01
Net Debt to EBITDA0.44
Interest Coverage Ratio-1.67K
Taxes
In the past 12 months, Reviva Pharmaceuticals Holdings has paid 19.51K in taxes.
Income Tax19.51K
Effective Tax Rate>-0.01
Enterprise Valuation
Reviva Pharmaceuticals Holdings EV to EBITDA ratio is -1.57, with an EV/FCF ratio of -1.40.
EV to Sales0.00
EV to EBITDA-1.57
EV to Free Cash Flow-1.40
EV to Operating Cash Flow-1.40
Balance Sheet
Reviva Pharmaceuticals Holdings has $10.36M in cash and marketable securities with $113.25K in debt, giving a net cash position of $10.25M billion.
Cash & Marketable Securities$10.36M
Total Debt$113.25K
Net Cash$10.25M
Net Cash Per Share$0.11
Tangible Book Value Per Share$0.02
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Reviva Pharmaceuticals Holdings is $5.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$5.14
Price Target Upside678.79% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast58.55%